Vanda Pharmaceuticals Inc
VNDA
NASDAQ
Biotechnology
$5.22
USD
+0.19 (+3.78%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $304.35M
Volume 964.6K
Revenue
$217.78M
TTM
+8.2%
YoY
Gross Margin
94%
TTM
-0.2%
YoY
Net Income
$-239.55M
TTM
-441.4%
YoY
Operating Cash Flow
$-126.51M
TTM
-124.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 50.0 | 52.6 | 56.3 | 57.2 | 51.7 |
YoY Growth | +5.4% | +4.2% | +18.1% | +7.6% | +3.4% |
Cost of Revenue | 3.5 | 2.7 | 3.0 | 3.8 | 3.2 |
Gross Profit | 46.5 | 49.9 | 53.3 | 53.4 | 48.6 |
Selling, General & Administrative | 50.1 | 64.6 | 60.3 | 63.0 | 68.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 87.5 | 88.4 | 84.6 | 93.7 | 98.8 |
Operating Income | -41.0 | -38.5 | -31.3 | -40.4 | -50.2 |
EBITDA | -39.0 | -36.5 | -29.2 | -38.3 | -48.0 |
Other Income / Expense | 3.7 | 3.6 | 2.9 | 2.4 | 1.8 |
Total Other Income / Expense | 3.7 | 3.6 | 2.9 | 2.4 | 1.8 |
Income Before Income Taxes | -37.4 | -34.9 | -28.4 | -38.0 | -48.4 |
Income Taxes | -7.9 | -7.7 | -5.8 | 103.2 | 0.1 |
Net Income | -29.5 | -27.2 | -22.6 | -141.2 | -48.6 |
Consolidated Net Income / Loss | -29.5 | -27.2 | -22.6 | -141.2 | -48.6 |
Net Income Attributable to Common Shareholders | -29.5 | -27.2 | -22.6 | -141.2 | -48.6 |
Basic EPS | -$0.50 | -$0.46 | -$0.38 | -$2.39 | -$0.82 |
Diluted EPS | -$0.50 | -$0.46 | -$0.38 | -$2.39 | -$0.82 |
Basic Shares Outstanding | 58.5M | 59.0M | 59.1M | 59.1M | 59.5M |
Diluted Shares Outstanding | 58.5M | 59.0M | 59.1M | 59.1M | 59.5M |